Table 3 Vaccine effectiveness of PPV23 in adults ≥75 years, estimated by the screening method, July 2008 to June 2016
IPD | VE | (95% CI) |
|---|---|---|
All serotypes | ||
Crude VE | 32.4% | (23.6 to 40.2) |
Adjusted by gender | 33.2% | (24.4 to 40.9) |
Adjusted by age and gender | 33.9% | (25.2 to 41.5) |
Death within 30 days of IPD onset | ||
Crude VE | 29.9% | (14.4 to 42.6) |
Adjusted by gender | 30.8% | (15.5 to 43.4) |
Adjusted by age and gender | 32.5% | (17.5 to 44.7) |
PPV23 VT | ||
Crude VE | 42.2% | (33.0 to 50.2) |
Adjusted by gender | 42.9% | (33.8 to 50.7) |
Adjusted by age and gender | 43.4% | (34.4 to 51.2) |
PPV23-non PCV13 VT | ||
Crude VE | 71.8% | (50.0 to 84.2) |
Adjusted by gender | 72.1% | (50.5 to 84.3) |
Adjusted by age and gender | 72.6% | (51.4 to 84.6) |
PCV13 (without 6A) VT | ||
Crude VE | 38.4% | (28.1 to 47.1) |
Adjusted by gender | 39.1% | (29.0 to 47.8) |
Adjusted by age and gender | 39.6% | (29.5 to 48.2) |